Personalis Appoints Industry Executive Aaron Tachibana as Chief Financial Officer

April 2, 2019

Menlo Park, CA – April 2, 2019 – Personalis, Inc., a leader in advanced genomics for cancer, today announced the appointment of Aaron Tachibana as Chief Financial Officer.

“We are very pleased to welcome Aaron to the Personalis team. He has an impressive track record and a wealth of global business operations and corporate finance experience in technology-driven companies, which will serve us well as we continue to introduce our ImmunoID NeXT Platform,” said John West, President and Chief Executive Officer of Personalis. “In his prior roles, Aaron has proven himself as a dynamic leader capable of building core infrastructure in large, medium, and small enterprises, and of driving value creation in highly competitive industries.  His extensive experience will provide critical knowledge and support as we advance Personalis.”

Most recently, Mr. Tachibana served as Chief Financial Officer of Lumentum Holdings Inc. (NASDAQ: LITE), where he oversaw all finance, information technology, legal, facilities, and real estate functions.  He also built and led the finance organization following Lumentum’s spin out from JDS Uniphase Corp. and transition into an independent, publicly-traded company.  Prior to joining Lumentum, Mr. Tachibana was Vice President of Finance at JDS Uniphase (which changed its name to Viavi Solutions Inc. in connection with the spin out of Lumentum), where he led the corporate accounting organization. He holds a B.S. in Business Administration and Finance from San Jose State University.

“I am excited to be joining Personalis during this stage of growth,” said Mr. Tachibana. “The executive team and employees have a tremendous amount of passion for enabling the next generation of cancer therapeutics and diagnostics, and I am invigorated by the opportunity to join this mission-driven company.”

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit and follow Personalis on Twitter (@PersonalisInc).

Media Contact for Personalis:
Jennifer Havlek